Cheng, Zhongshan
Phokaew, Chureerat
Chou, Yi-Ling
Lai, Dongbing
Meyers, Jacquelyn L.
Agrawal, Arpana http://orcid.org/0000-0002-0313-793X
Farrer, Lindsay A.
Kranzler, Henry R. http://orcid.org/0000-0002-1018-0450
Gelernter, Joel http://orcid.org/0000-0002-4067-1859
Funding for this research was provided by:
Foundation for the National Institutes of Health (AA11330, AA017535)
Article History
Received: 31 January 2019
Revised: 1 July 2019
Accepted: 11 August 2019
First Online: 18 November 2019
Conflict of interest
: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. Kranzler has been a consultant or advisory board member for Alkermes, Indivior, and Lundbeck. He is a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor, and Amygdala Neurosciences. Drs. Kranzler and Gelernter are named as inventors on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed 24 January 2018. The other authors have no biomedical financial interests or potential conflicts of interest.